Category «Uncategorized»

Nerandomilast

Nerandomilast CAS 1423719-30-5 C20H25ClN6O2S Molecular Weight 448.97 Formula C20H25ClN6O2S I5DGT51IB8 fda 2025, approvals 2025, Jascayd,10/7/2025, To treat idiopathic pulmonary fibrosis [1-[[(5R)-2-[4-(5-chloropyrimidin-2-yl)piperidin-1-yl]-5-oxo-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl]amino]cyclobutyl]methanol Cyclobutanemethanol, 1-[[(5R)-2-[4-(5-chloro-2-pyrimidinyl)-1-piperidinyl]-6,7-dihydro-5-oxidothieno[3,2-d]pyrimidin-4-yl]amino]- 1-[[(5R)-2-[4-(5-Chloro-2-pyrimidinyl)-1-piperidinyl]-6,7-dihydro-5-oxidothieno[3,2-d]pyrimidin-4-yl]amino]cyclobutanemethanol Nerandomilast (BI 1015550) is an investigational oral medication being studied for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). It is a preferential inhibitor of phosphodiesterase 4B (PDE4B) and …

Nedometinib

Nedometinib CAS 2252314-46-6 NFX-179, K5T4I78IYZ Molecular Weight 470.24 Formula C17H16FIN4O3 2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1-methylpyrrolo[2,3-b]pyridine-3-carboxamide Nedometinib (NFX-179) is a specific MEK1 inhibitor with an IC50 of 135 nM. Nedometinib inhibits p-ERK, MAPK. Nedometinib exerts anticancer activity against squamous cell carcinoma. Nedometinib can be used for research in dermatosis, neurofibromatosis. Nedometinib is a topical gel formulation composed of an inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPKK; MEK), with …

Modoflaner

Modoflaner ‘ Molecular Weight 715.23 Formula C23H10F12IN3O2 CAS No. 1331922-53-2 6-fluoro-N-[2-fluoro-3-[[4-(1,1,1,2,3,3,3-heptafluoropropan-2-yl)-2-iodo-6-(trifluoromethyl)phenyl]carbamoyl]phenyl]pyridine-3-carboxamide E583FHZ8C9 Modoflaner is an isophenylamide insecticide. Modoflaner may act through allosteric regulation of gamma-aminobutyric acid-gated chloride channels. SCHEME PATENT WO2019059412 https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019059412&_cid=P20-MC71WG-08056-1 SYN Modoflaner is another isophthalamide insecticide developed by Mitsui Chemicals Agriculture Co., Ltd. in Japan. Its structure is similar to broflanilide and cyproflanilide created in …

MIVORILANER

MIVORILANER 1414642-93-5 Molecular Formula C22H17Cl2F6N3O3S Molecular Weight 588.35 1-[(5S)-5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4H-1,2-oxazol-3-yl]-N-[2-(2,2-difluoroethylamino)-2-oxoethyl]-5,6-dihydro-4H-cyclopenta[c]thiophene-3-carboxamide MIVORILANER is a small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication. Mivorilaner, an antineoplastic, can be used for the research of veterinary medicine SCHEME PATENT WO2012155676 (S)-3-[5-(3,5-dichloro-4-fluoro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-5,6-dihydro-4H-cyclopenta[c]thiophene-1-carboxylic acid [(2,2-difluoro-ethylcarbamoyl)-methyl]-amide 3 g of 3-[5-(3,5-dichloro-4-fluoro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-5,6-dihydro-4H-cyclopenta[c]thiophene-1-carboxylic acid [(2,2-difluoro-ethylcarbamoyl)-methyl]-amide is separated by …

LEVALBUTEROL TARTRATE

LEVALBUTEROL TARTRATE Levosalbutamol cas 661464-94-4 4-[(1R)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;(2R,3R)-2,3-dihydroxybutanedioic acid 1,3-BENZENEDIMETHANOL, alpha(SUP 1)-(((1,1-DIMETHYLETHYL)AMINO)METHYL)-4-HYDROXY-, (alpha(SUP 1)R)-, (2R,3R)-2,3-DIHYDROXYBUTANEDIOATE (2:1) (SALT) MW 628.7, C30H48N2O12 Levalbuterol Tartrate is the tartrate salt form of levalbuterol, the R-enantiomer of the short-acting beta-2 adrenergic receptor agonist albuterol, with bronchodilator activity. Levalbuterol selectively binds to beta-2 adrenergic receptors in bronchial smooth muscle, thereby activating intracellular adenyl cyclase, an enzyme that catalyzes the …

Zilucoplan

Zilucoplan CAS 1841136-73-9 YG391PK0CC, RA101495, WHO 10602 3562 g/mol, C172H278N24O55 Zilucoplan lso designated as RA101495, is the active principle of Zilbrysq®, commercialized by UCB Pharma S.A. It is a 3.5 kDa synthetic macrocyclic peptide composed of 15 amino acid residues, including four unnatural amino acids [27]. The amino acid residues composition is: L-Lys, L-Val, L-Glu, L-Arg, …

Labuxtinib

Labuxtinib CAS 1426449-01-5 Labuxtinib, also known as EVT-8565072, Molecular Weight 377.37 Formula C20H16FN5O2 Labuxtinib is c-kit tyrosine kinase inhibitor. Labuxtinib, also known as EVT-8565072, is a synthetic organic compound that acts as a tyrosine kinase inhibitor, specifically targeting c-KIT. It is a potential anti-cancer agent and is likely the INN (Proposed International Nonproprietary Name) for Third Harmonic Bio‘s candidate KIT inhibitor, THB335. The initial clinical …

Gepirone

Gepirone CAS 83928-76-1 BMY 13805, MJ 13805, ORG 13011, Gepirona, JW5Y7B8Z18 FDA 9/22/2023, Gepirone is indicated for the treatment of major depressive disorder (MDD) in adults Exxua WeightAverage: 359.474Monoisotopic: 359.232125194Chemical FormulaC19H29N5O2 4,4-dimethyl-1-{4-[4-(pyrimidin-2-yl)piperazin-1-yl]butyl}piperidine-2,6-dione Ingredient UNII CAS InChI Key Gepirone Hydrochloride 80C9L8EP6V 83928-66-9 DGOCVISYYYQFEP-UHFFFAOYSA-N Gepirone, sold under the brand name Exxua, is a medication used for the treatment of major depressive …

HEXASODIUM PHYTATE

HEXASODIUM PHYTATE cas 34367-89-0 myo-Inositol, 1,2,3,4,5,6-hexakis(dihydrogen phosphate) sodium salt (1:6) hexasodium;[2,3,4,5,6-pentakis[[hydroxy(oxido)phosphoryl]oxy]cyclohexyl] hydrogen phosphate free form RN: 83-86-3 C6H12Na6O24P6, 791.93 x Na salt 14306-25-3 C6H18O24P6.xNa free form : 83-86-3 myo-Inositol, 1,2,3,4,5,6-hexakis(dihydrogen phosphate), sodium salt (1R,2R,3S,4S,5R,6S)-CYCLOHEXANE-1,2,3,4,5,6-HEXAYL-HEXAKIS(DIHYDROGEN PHOSPHATE) INOSITOL, HEXAKIS(DIHYDROGEN PHOSPHATE) HEXASODIUM SALT, MYO- Hexasodium phytate (also known as SNF472) is a compound being developed as a potential treatment for calciphylaxis, …

Ibuzatrelvir

Ibuzatrelvir PF-07817883 CAS 2755812-39-4 Molecular Weight 489.49 Formula C21H30F3N5O5 Ibuzatrelvir (development code PF-07817883) is an experimental antiviral drug being developed by Pfizer for the treatment of COVID-19.[1] It is a second-generation improvement over nirmatrelvir which has a similar chemical structure.[2] One of the disadvantages of nirmatrelvir is that it has low metabolic stability and must be given in combination with ritonavir (as Paxlovid) to limit its metabolic degradation in the body.[3] Ibuzatrelvir …